GWLL GOLDENWELL BIOTECH, INC.
Food and Kindred Products · OTC · SEC CIK 1800373 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-94.1%
TTM net income YoY-12.4%
TTM EPS YoY—
Revenue 3-yr CAGR-79.9%
Net income 3-yr CAGR—
Margins
Gross margin50.4%
Operating margin-88,556.1%
Net margin-94,542.4%
FCF margin—
EBITDA margin—
Returns
ROE-710.0%
ROA-58.1%
ROIC (approx.)-125.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets121.1%
Debt / equity—
Current ratio—
Interest coverage-14.65x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-6.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $55 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $43 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $12 | $0 | $0 | $0 | $0 |
| SG&A expense | $29,440 | $34,776 | $31,335 | $22,907 | $25,795 | $28,200 | $36,436 | $25,352 |
| Operating income | -$29,440 | -$34,776 | -$31,335 | -$22,895 | -$25,795 | -$28,200 | -$36,436 | -$25,352 |
| Interest expense | — | — | $2,100 | $2,100 | $2,100 | $2,100 | $2,100 | $2,100 |
| Pretax income | — | — | — | — | — | — | -$34,377 | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$31,540 | -$36,876 | -$17,606 | -$199,740 | -$27,895 | -$30,300 | -$38,536 | -$27,452 |
| EPS (diluted) | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 99.00M | 99.00M | 99.00M | — | 99.00M | 99.00M | 99.00M | — |
| Banking | ||||||||
| Noninterest expense | — | — | — | — | — | — | $2,100 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $788 | $11,143 | $13,414 | $26,775 | $45,622 | $76,507 | $17,127 | $49,404 |
| Inventory | — | $0 | $0 | $174,745 | $174,788 | $174,788 | $174,788 | $174,788 |
| Total assets | $14,538 | $28,978 | $18,754 | $36,120 | $233,760 | $267,315 | $191,915 | $224,192 |
| Current liabilities | $100,000 | $100,000 | $100,000 | $101,860 | $101,860 | $109,620 | — | $1,860 |
| Long-term debt | — | — | — | — | — | — | $176,085 | $173,985 |
| Total debt | — | — | — | — | — | — | $176,085 | $173,985 |
| Total liabilities | $444,273 | $427,173 | $380,073 | $424,833 | $377,733 | $383,393 | $277,693 | $271,433 |
| Shareholders' equity | -$429,735 | -$398,195 | -$361,319 | -$343,713 | -$143,974 | -$116,078 | -$85,778 | -$47,241 |
| Net debt | — | — | — | — | — | — | $158,958 | $124,581 |
| Shares outstanding | 99.00M | 99.00M | 99.00M | 99.00M | 99.00M | 99.00M | 99.00M | 99.00M |
| Cash flow statement | ||||||||
| Operating cash flow | -$25,355 | -$47,271 | -$13,361 | -$18,848 | -$30,885 | $59,380 | -$32,276 | -$19,051 |
| Financing cash flow | $15,000 | $45,000 | $0 | $0 | $0 | $0 | $0 | $63,700 |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.